Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis.

Ryma Ihaddadene 1 Grégoire Le Gal 2 Aurélien Delluc 2, 3 Marc Carrier 1, 4, *
* Auteur correspondant
1 PSW - Clinical Epidemiology Program
2 GETBO - Groupe d'Etude de la Thrombose de Bretagne Occidentale
3 DMIP - Brest - Département de Médecine Interne et Pneumologie [Brest]
4 Thrombosis Program
Abstract : INTRODUCTION: Patients with cancer-associated thrombosis are at a high risk of developing recurrent events despite anticoagulant therapy. Escalation of the dose of low molecular weight heparin (LMWH) has been suggested as a potential treatment option to manage these patients. We sought to confirm the benefit and risk of this management strategy in patients with recurrent cancer-associated thrombosis. MATERIAL AND METHODS: A retrospective cohort study of consecutive cancer outpatients seen for management of a symptomatic recurrent cancer-associated thrombosis while on anticoagulation was undertaken. Objectively confirmed episodes of recurrent thrombosis were treated with either dose escalation of LMWH or initiation of therapeutic dose of LMWH in patients already anticoagulated with LMWH or vitamin K antagonist (VKA) respectively. Included patients were followed for a minimum of 3months after the index recurrent event. RESULTS: Fifty-five cancer patients with a recurrent venous thromboembolism (VTE) despite anticoagulation were included. At the time of the recurrence, 89% of patients were on LMWH. The median time between the initial cancer-associated thrombosis to the index recurrent event was 2.3months (range 0.1 to 30.4months). Four patients (7.3%; 95% CI: 2.0 to 17.6%) had a second recurrent VTE during the 3-month follow-up period. Three patients (5.5%; 95% CI 1.1 to 15.1%) had major bleeding complications after dose escalation of LMWH. There were no recurrent fatal VTE or major bleeding episodes. CONCLUSION: Escalating the dose of LMWH seems effective and safe for managing patients with recurrent cancer-associated thrombosis despite anticoagulant therapy.
Type de document :
Article dans une revue
Thrombosis Research, Elsevier, 2014, 134 (1), pp.93-5. 〈10.1016/j.thromres.2014.04.028〉
Liste complète des métadonnées
https://hal.univ-brest.fr/hal-01026426
Contributeur : Ghislaine Calvez <>
Soumis le : lundi 21 juillet 2014 - 15:51:41
Dernière modification le : jeudi 7 février 2019 - 14:50:14

Identifiants

Collections

UNIV-BREST | GETBO | IBSAM

Citation

Ryma Ihaddadene, Grégoire Le Gal, Aurélien Delluc, Marc Carrier. Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis.. Thrombosis Research, Elsevier, 2014, 134 (1), pp.93-5. 〈10.1016/j.thromres.2014.04.028〉. 〈hal-01026426〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

72

Contact

support.ccsd.cnrs.fr
hal.support@ccsd.cnrs.fr
Logo CCSD